Related Experiment Video

Updated: Mar 6, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Biological therapies in nonsmall cell lung cancer

Jon Zugazagoitia1,2,3,4, Sonia Molina-Pinelo1,2,3,4, Fernando Lopez-Rios3,5

  • 1Medical Oncology Dept, Hospital Universitario 12 de Octubre and Instituto de Investigación i+12, Madrid, Spain.

The European Respiratory Journal
|March 4, 2017
PubMed

Insights

Biological therapies, including genotype-directed treatments and immune checkpoint inhibitors, are improving survival for advanced nonsmall cell lung cancer (NSCLC). These targeted approaches offer new hope for patients with specific genetic mutations and advanced NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Advanced-stage nonsmall cell lung cancer (NSCLC) survival has been improved by biological therapies.
  • Genotype-directed therapies have transformed treatment for EGFR-mutant and ALK/ROS1-rearranged lung adenocarcinomas.
  • Understanding cancer immune evasion mechanisms has led to strategies to overcome them, particularly via immune checkpoint inhibition.

Purpose of the Study:

  • To review the role of medical disciplines in managing advanced-stage NSCLC.
  • To discuss the most relevant biological therapies for advanced NSCLC.
  • To emphasize genotype-directed therapies and immune checkpoint inhibitors.

Main Methods:

  • Literature review of biological therapies for advanced NSCLC.
  • Discussion of genotype-directed treatments targeting specific mutations (EGFR, ALK/ROS1, BRAF, MET, RET, NTRK1, HER2).
  • Review of immune checkpoint inhibitors, focusing on PD-1 pathway drugs.

Main Results:

  • Biological therapies, especially genotype-directed and immune checkpoint inhibitors, have significantly improved outcomes in advanced NSCLC.
  • Expanding list of actionable molecular targets (BRAF, MET, RET, NTRK1, HER2) enhances personalized treatment strategies.
  • PD-1 pathway inhibitors demonstrate remarkable benefits, offering potential long-term survival for a subset of patients.

Conclusions:

  • Biological therapies represent a paradigm shift in advanced NSCLC management.
  • Genotype-directed therapies and immune checkpoint inhibitors are crucial components of modern NSCLC treatment.
  • Continued research into molecular targets and immune evasion mechanisms promises further advancements.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.4K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K